ID | 1118 |
Name of the vaccine | Typbar TCV |
Microbe | Bacteria |
Disease name | Typhoid |
Name of bacteria | Salmonella typhi |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | From 6 months |
Description of the vaccine | World’s first Typhoid conjugate vaccine. |
Name of the manufacturer | Bharat Biotech |
Name of the manufacturing country | India |
Year of manufacture | 2013 |
Clinical Phase status | Approved |
Bacterial strain | Gram negative bacteria. |
Efficacy | Protective efficacy of 87% against typhoid fever. |
Vaccine formulation | Turbid liquid |
Dosage | Single dose of 0.5 mL and a booster dose may be given after 3 years. |
Mechanism of action | T-cell dependent, induces Vi antibodies that neutralize Vi antigen. |
Route of administration | Intramuscular |
Indications | Long term protection against typhoid fever. |
Export | Marketed by : Bharat Biotech International Ltd, India |
Approval | WHO pre-qualified |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Pain at injection site, swelling, fever and headache. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf |
Other name | NA |
Additional Links | https://www.bharatbiotech.com/images/typbartcv/Typbar-TCV-Package-Insert.pdf
|